Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 2, 2001, Pages 525-531

  Siami, G ^a   Christou, N ^a   Eiseman, I ^a   Tack, K J ^a   Parish, L ^a   Boulevard, J F K ^a   Nicolle, L ^a   Zervos, M ^a   Wilson, S ^a   Caldwell, J ^a   Talan, D ^a   Lipsky, B ^a   Ramirez, J ^a   Liu, H ^a   Tan, J ^a   Lee, T ^a   Heard, S ^a   Breen, J ^a   Kirmani, N ^a   Gremillion, D ^a   Resnick, H ^a   Rumans, L ^a   Metzler, M ^a   Wolf, J ^a   Geckler, R ^a   Kirsner, R ^a   Napoli, J ^a   Sawchuck, A ^a   Danziger, L ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINAFLOXACIN; METICILLIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC FOOT; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; ERADICATION THERAPY; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; PHOTOTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; WOUND INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMASES; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; PENICILLANIC ACID; PENICILLINS; PIPERACILLIN; SKIN DISEASES, INFECTIOUS;

EID: 0035145047     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.2.525-531.2001     Document Type: Article

References (37)

1. Susceptibility survey of piperacillin alone and in the presence of tazobactam
2. Categorical data analysis
3. Wound healing in diabetes: Outcome and costs
4. Expanded activity and utility of the new fluoroquinolones: A review
5. General guidelines for the evaluation of new anti-infective drugs and for the treatment of skin, skin structure, bone, and joint infections
6. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin
7. Activity of ciprofloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin
8. Analysis of antibiotic susceptibilities of skin wound flora in hospitalised dermatology patients
9. Comparison of the efficacy and safety of once-daily oral trovafloxacin and 3-times daily amoxicillin/clavulanic acid for the treatment of complicated skin and soft-tissue infections
10. Once daily oral trovafloxacin in the treatment of diabetic foot infections
11. Structure-activity and structure-side-effect relationships for the quinolone antibacterials
12. Optimum outpatient therapy of skin and skin structure infections
13. Treatment of skin and soft-tissue infections
14. Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections
15. Ticarcillin-clavulanate therapy for bacterial skin and soft tissue infections
16. In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents
17. Review of quinolones in the treatment of infections of the skin and skin structure
18. Treatment of skin and soft tissue infections with quinolone antimicrobial agents
19. Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections
20. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin
21. Interpretative criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-μg disks
22. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: The role of streptogramins and other newer compounds
23. Microbiology and antimicrobial therapy of diabetic foot infections
24. Fluoroquinolone treatment of skin and skin structure infections
25. Antibiotic therapy for diabetic foot infections: Comparison of two parenteral-to-oral regimens
26. Safety and tolerability of fluoroquinolones
27. Systemic antimicrobial therapy for skin and skin structure infections: Comparison of fleroxacin and ceftazidime
28. Quinolone resistance-susceptibility data from a 300-bed community hospital
29. Pharmacokinetics of oral and intravenous clinafloxacin
30. Surgical skin and soft tissue infections
31. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329998, CL 331002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against gram-positive bacteria
32. Initial clinical experience with clinafloxacin in the treatment of serious infections
33. Treatment of hospitalized patients with complicated skin and skin structure infections: Double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate
34. Future management of serious infections with quinolones: Place of clinafloxacin
35. Pharmacokinetics and inflammatory fluid penetration of clinafloxacin